The expression and significance of WT1 in xenotransplanted ovarian carcinoma treated by paclitaxel

In this study, the authors investigated the expression and significance of WT1 in xenotransplanted ovarian carcinoma cell SKOV3 of nude mice treated with paclitaxel. Xenotransplanted ovarian carcinoma was established in nude mice using the SKOV3 cell line. The mice were randomized into the treatment group with paclitaxel and control group with normal sodium. The sizes of the xenotransplanted tumors were measured and the tumor specimens were confirmed by routine hemotoxylin-eosin (H&E) staining. The apoptosis index was then assayed using flow cytometry. WT1 and bcl-2 expression were detected with immunohistochemistry, and WT1 mRNA expression was determined by reverse transcriptase polymerase chain reaction (RT-PCR). The authors found that the growth of the xenotransplanted tumor was inhibited by paclitaxel therapy. Compared to the control group, the apoptosis rate was significantly increased in the treatment group (p < 0.05). At the same time, the expression of WT1, bcl-2 and WT1, mRNA were significantly decreased in the paclitaxel therapy group (p < 0.05). The authors conclude that the WT1 gene may play an important role during apoptosis of ovarian carcinoma and the mechanism may be closely related to bcl-2.

Ovarian carcinoma; Xenotransplanted carcinoma of nude mice; Paclitaxel; WT1.

[1] McGuire W.P., Rowinsky E.K., Rosenshein N.B., Grumbine F.C., Ettinger D.S., Armstrong D.K., et al.: “Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms”. Ann. Intern. Med., 1989, 111, 273.

[2] Xiaoxi Huo, Xiaojun Liu, Li Yang, Yan Liu.: “Expression of WT1 Protein in Ovarian Epithelial Carcinoma and Their Clinicopathological Significance”. People’s Military Surgeon, 2009, 52, 167.

[3] Yamashita M., Kajiyama H., Terauchi M., Shibata K., Ino K., Nawa A., et al.: “Involvement of aminopeptidase N in enhanced chemosensitivity to Paclitaxel in ovarian carcinoma in vitro and in vivo”. Int. J. Cancer, 2007, 120, 2243.

[4] Loeb D.M., Evron E., Patel C.B., Sharma P.M., Niranjan B., Buluwela L., et al.: “Wilms tumor suppression gene WT1 is expressed in primary breast tumors despite tumor-specifit promoter methylation”. Cancer Res., 2001, 61, 921.

[5] Hylander B., Repasky E., Shrikant P., Intengan M., Beck A., Driscoll D., et al.: “Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer”. Gynecol. Oncol., 2006, 101, 12.

[6] Wang Z.Y., Qiu Q.Q., Deuel T.F.: “The Wilms' tumor gene product WT1 activates or supresses transcription through separate functional domains”. Biol. Chem., 1993, 268, 9172.

[7] Hewitt S.M., Hamada S., McDonnell T.J., Rauscher F.J. 3rd, Saunders G.F.: “Regulation of the pro-onco genes bcl-2 and c-myc by the Wilms’tumorsupressor gene WT1”. Cancer Res., 1995, 55, 5386.

[8] Wang T.H., Wang H.S., Soong Y.K.: “Paclitaxel-induced cell death: where the cell cycle and apoptosis come together”. Cancer, 2000, 88, 2619.

[9] Li F., Ackermann E.J., Bennett C.F., Rothermel A.L., Plescia J., Tognin S., et al.: “Pleiotropic cell division defects and apoptosis induced by interference with surviving function”. Nat. Cell, 1999, 1,461.

[10] Haldar S., Basu A., Croce C.M.: “Serine-70 is one of the critical sites for drug-induced Bc1-2 phosphorylation in cancer cells”. Cancer Res., 1998, 58, 1609.

[11] Cory S., Huang D.C., Adams J.M.: “The bcl-2 family: roles in cell survival and oncogenesis”. Oncogene, 2003, 22, 8590.

[12] Beale P.J., Rogers P., Boxall F., Sharp S.Y., Kelland L.R.: “Bcl-2 family protein expression and platinum drug resistance in ovarian carcinoma”. Br. J. Cancer, 2000, 82, 436.

[13] Lohmann C.M., League A.A., Clark W.S., Lawson D., DeRose P.B., Cohen C.: “Bcl-2:bax and bcl-2:bcl-x rations by image cytometric quantitation of immunohistochemicalexpression in ovarian carcinoma: correlation with prognosis”. Cytometry, 2000, 42, 61.

[14] ChandlerD., el-NaggarA.K., Brisbay S., Redline R.W., McDonnell T.J.: “Apoptosis and exprssion of the bcl-2 pro-oncogene in the fetal and adult human kidney evidence for the contribution of bcl-2 expression to renal carcinogenesis”. Hum. Pathol., 1994, 25, 789.

[15] Mayo M.W., Wang C.Y., Drouin S.S., Madrid L.V., Marshall A.F., Reed J.C., et al.: “WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene”. EMBO J., 1999, 18, 3990.